Specific Increase in p85alpha Expression in Response to Dexamethasone Is Associated with Inhibition of Insulin-like Growth Factor-I Stimulated Phosphatidylinositol 3-Kinase Activity in Cultured Muscle Cells*

(Received for publication, September 11, 1996, and in revised form, November 26, 1996)

Francesco Giorgino Dagger §, Michael T. Pedrini Dagger par , Lucrezia Matera § and Robert J. Smith Dagger **

From the Dagger  Research Division, Joslin Diabetes Center, and Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02215 and the § Istituto di Clinica Medica, Endocrinologia e Malattie Metaboliche, University of Bari School of Medicine, Bari, Italy 70124

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
Acknowledgment
REFERENCES


ABSTRACT

The stimulation of phosphatidylinositol (PI) 3-kinase by insulin-like growth factor I (IGF-I) in L6 cultured skeletal muscle cells is inhibited by the glucocorticoid dexamethasone. The objective of this study was to investigate the mechanism of dexamethasone action by determining its effects on the expression of the p85alpha and p85beta regulatory subunit isoforms of PI 3-kinase, their coupling with the p110 catalytic subunit, and their association with insulin receptor substrate 1 (IRS-1) in response to IGF-I stimulation. Dexamethasone induced a 300% increase in p85alpha protein content in the L6 cultured myoblast cell line, whereas it increased p110 content by only 38% and had no effect on p85beta . The increase in p85alpha protein was associated with a coordinate increase in p85alpha mRNA. Stimulation with IGF-I induced the association of p85alpha and p85beta with IRS-1, and this was accompanied by increased amounts of the p110 catalytic subunit and markedly increased PI 3-kinase activity in IRS-1 immunoprecipitates. In cells treated with dexamethasone, greater amounts of p85alpha and lower amounts of p85beta , respectively, were found in IRS-1 immunoprecipitates, such that the alpha /beta ratio was markedly higher than in control cells. In spite of the increase in both total and IRS-1-associated p85alpha following dexamethasone treatment, IRS-1-associated p110 catalytic subunit and PI 3-kinase activity were decreased by approximately 50%. Thus, dexamethasone induces a specific increase in expression of the p85alpha regulatory subunit that is not associated with a coordinate increase in the p110 catalytic subunit of PI 3-kinase. As a consequence, in dexamethasone-treated cells, p85alpha that is not coupled with p110 competes with both p85alpha ·p110 and p85beta ·p110 complexes for association with IRS-1, leading to increased p85alpha but decreased p85beta , p110, and PI 3-kinase activity in IRS-1 immunoprecipitates.


INTRODUCTION

Growth factor activation of transmembrane tyrosine kinase receptors results in rapid recruitment of phosphatidylinositol (PI)1 3-kinase activity to tyrosine-phosphorylated proteins. In intact cells, PI 3-kinase catalyzes the phosphorylation of PI 4,5-bisphosphate (PI-4,5-P2) at the 3'-position of the inositol ring, thus leading to elevation in intracellular PI 3,4,5-trisphosphate (PI-3,4,5-P3) (reviewed in Ref. 1). Unlike the products of PI kinases in the classical PI cycle (PI-4-P and PI-4,5-P2), 3-phosphorylated phosphoinositides are not cleaved by phospholipase C-gamma (2, 3), and it has been suggested that they may serve as intracellular second messengers for yet unidentified in vivo targets (1, 4). Extensive experimental evidence has established a key role for PI 3-kinase in the signal transduction mechanisms of a number of peptide growth factors, including epidermal growth factor, platelet-derived growth factor (PDGF), insulin, and insulin-like growth factor-I (IGF-I). PI 3-kinase has thus been implicated in the regulation of multiple general and specialized cellular processes, including membrane ruffling (5), receptor endocytosis (6), mitogenesis (7, 8), cell differentiation (9), and insulin stimulation of glucose transport (10-12) and glycogen synthesis (13, 14).

Mammalian PI 3-kinase is a heterodimer composed of an 85-kDa (p85) regulatory subunit and a 110-kDa (p110) catalytic subunit (15, 16). Two distinct and closely related 85-kDa protein isoforms, p85alpha and p85beta , have been cloned and shown to be the products of separate genes (17-20). Both of these p85 proteins have the capacity to form stable high affinity complexes with the p110 component of PI 3-kinase (21, 22). The two p85 isoforms have a multidomain structure, containing two SH2 (src homology 2) domains, one SH3 domain, and a region with significant sequence similarity to a GTPase-activating protein domain of the product of the breakpoint cluster region gene (23). The presence of several functional domains suggests that the p85 proteins may have multiple interactive and regulatory roles. At present, functional differences between the p85alpha and p85beta protein isoforms have not been established.

Two forms of p110 also have been cloned, one from bovine brain designated p110 (20), and a second human variant designated p110beta (24). Expression studies have demonstrated that both p110 proteins have intrinsic PI 3-kinase activity and can associate with the p85 component in intact cells (20, 24). The domains in p85 and p110 required for subunit interaction have been identified and mapped to an amino acid sequence between the two SH2 domains of p85 and an NH2-terminal amino acid sequence of p110, respectively (20, 25-27). These studies have established a structural model of the PI 3-kinase complex, in which the p110 subunit contains catalytic activity and is tightly associated with the p85 subunit, which acts as an adaptor and/or regulatory subunit. Integrity of the p85·p110 complex appears to be necessary for p110 catalytic activity (26). Thus, overexpression of the p85 subunit or a portion of the p85 protein, such as an intact p85 SH2 domain, through transfection or microinjection of cells results in inhibition of PI 3-kinase activation and cell signaling (28, 29). The physiological occurrence of selective up-regulation of p85 expression as a mechanism of inhibition of PI 3-kinase activity has not been investigated.

The best characterized mode of PI 3-kinase activation in response to peptide growth factors involves changes induced in the p85 protein upon binding to certain phosphorylated tyrosine residues, which are then transmitted to the associated p110 catalytic subunit and cause its activation. In the case of the epidermal growth factor and PDGF receptors, the p85 protein binds directly to phosphorylated tyrosines in the receptor molecule through its SH2 domains (reviewed in Ref. 1). In the case of the receptors for insulin and IGF-I, only a limited fraction of the total cell PI 3-kinase associates directly with the receptor, while most of PI 3-kinase interacts with specific tyrosine-phosphorylation sites of the receptor substrates IRS-1 and IRS-2 (30-32). Binding of p85alpha to tyrosine-phosphorylated IRS-1 or phosphorylated IRS-1-related YMXM peptide sequences results in increased catalytic activity of the PI 3-kinase complex (33, 34). Tyr-608 and Tyr-939 of IRS-1 appear to be the predominant sites for interaction with the amino-terminal SH2 domain of p85alpha (35). Although these studies have provided important insight into the mechanism of PI 3-kinase activation in response to insulin and IGF-I, limited information is available on the relative abundance of p85alpha and p85beta within the IRS-1·PI 3-kinase complex and the coupling of IRS-1-associated p85 isoforms with catalytically active p110 subunits.

In a previous report (36), we described the inhibition of IGF-I activated PI 3-kinase activity by the glucocorticoid dexamethasone in the L6 skeletal muscle cell line. The objective of this study was to investigate the effects of dexamethasone on the expression of p85alpha and p85beta isoforms of PI 3-kinase in L6 cells, their coupling with the p110 catalytic subunit, and their association with IRS-1 in response to IGF-I stimulation. We show that L6 myoblasts express both p85alpha and p85beta and that the expression of p85alpha , but not that of p85beta , is specifically increased by dexamethasone. The increase in the cellular pool of p85alpha correlates with an increased amount of this protein associated with IRS-1 after IGF-I stimulation. However, despite the increase in IRS-1-associated p85alpha , both p110 and PI 3-kinase activity associated with IRS-1 are diminished. These data support the concept that a substantial fraction of p85alpha is "free" (i.e. not coupled with p110) in dexamethasone-treated cells. We propose that the selective increase in p85alpha expression may represent a novel physiological mechanism leading to inhibition of PI 3-kinase activity by glucocorticoids.


EXPERIMENTAL PROCEDURES

Reagents and Antibodies

Culture medium and donor calf bovine serum were from Life Technologies, Inc. Recombinant human insulin and recombinant human IGF-I were gifts from Eli Lilly (Indianapolis, IN). PDGF-BB was purchased from Genzyme (Boston, MA). Protein A-Sepharose was from Pierce (Rockford, IL). Reagents for SDS-PAGE and the Bradford protein assay were purchased from Bio-Rad. 125I-Labeled protein A and Tran35S-label were from ICN, [alpha -35S]dATP was from Amersham, and [gamma -32P]ATP was from DuPont NEN. Oligonucleotides were purchased from Bio-Synthesis (Lewisville, TX). Moloney murine leukemia virus-H- Reverse Transcriptase was from Life Technologies, Inc. Ampli-Taq polymerase and other reagents for PCR amplification were from Perkin Elmer. Dexamethasone and other chemicals were from Sigma.

Polyclonal phosphotyrosine (anti-PY) antibody was prepared in rabbits by injection of phosphotyrosine polymerized by 1-ethyl-3(3-dimethyl-aminopropyl)carbodiimide with alanine, threonine, and keyhole limpet hemocyanin, and purified by affinity chromatography on a phosphotyramine-Sepharose column as described previously (37). Polyclonal anti-peptide antibodies against a Tyr-Ala-Ser-Ile-Asn-Phe-Gln-Lys-Gln-Pro-Glu-Asp-Arg-Gln peptide, corresponding to the last 14 amino acids in the COOH-terminal region of rat IRS-1 (38), were generated and purified on specific peptide affinity columns as described previously (36, 37). Polyclonal anti-p85 (anti-p85) antibodies that recognize both alpha  and beta  isoforms of p85 were purchased from Upstate Biotechnology Inc. Monoclonal antibodies specific to p85alpha (anti-p85alpha ) were from Transduction Laboratories. Monoclonal antibodies to the p110 subunit of PI 3-kinase (anti-p110) were a generous gift of Dr. L. T. Williams (University of California, San Francisco, CA).

Cell Culture

The line of L6 rat skeletal muscle cells has been described previously (36). Cells were cultured in MEM supplemented with 10% donor calf bovine serum, 2 mM glutamine, and nonessential amino acids in a 5% CO2 atmosphere at 37 °C. Cells were plated in MEM containing 10% donor calf bovine serum in 150-mm culture dishes. On day 4 after plating, when the cells were 50-60% confluent, the medium was replaced with serum-free MEM containing 0.5% bovine serum albumin, and cells were incubated in the presence or absence of 1 µM dexamethasone (concentration confirmed by absorbance at 242 nm using a molar absorbance coefficient of 1.5 × 104 M-1 cm-1) for the indicated times. All experiments were carried out with undifferentiated myoblasts.

Analysis of p85alpha and p85beta mRNA Content

L6 cell monolayers were rinsed twice with ice-cold phosphate-buffered saline and solubilized directly on the tissue culture plates with 4 M guanidinium isothiocyanate, 0.1 M Tris-HCl, pH 7.5, 0.66% N-laurylsarcosine, and 5% beta -mercaptoethanol. Total cellular RNA was isolated by low temperature 4 M guanidinium isothiocyanate-phenol-chloroform extraction, followed by cold ethanol precipitation (39), and quantitated by spectrophotometry at 260 nm. In all samples, intact ribosomal RNA bands were visualized after electrophoresis. To quantitate p85alpha and p85beta mRNA content in L6 cells, a polymerase chain reaction (PCR) amplification method was used with oligonucleotide primers complementary to sequences that are identical or highly homologous in p85alpha and p85beta mRNA but flank regions of different sizes, such that amplified cDNA fragments from the two p85 isoforms could be separated by polyacrylamide gel electrophoresis (40). Specific first strand cDNA copies of p85alpha and p85beta mRNAs were synthesized using 100 units of Moloney murine leukemia virus-H- Reverse Transcriptase in a 20-µl reaction volume containing 3-5 µg of total cell RNA and 0.75 µM reverse primer 5'-GTACAGGTTGTAGGGCTC-3' at 42 °C. This primer is complementary to a nucleotide sequence that is identical in bovine p85alpha and p85beta (nucleotides 2064-2047 and 2046-2029 in p85alpha and p85beta cDNA sequences, respectively) and in bovine and mouse p85alpha (17, 19). The reverse transcription products were combined with 2.5 units of Ampli-Taq, 1 × PCR buffer, 100 µM dNTPs, 4 mM MgCl2, and 0.15 µM oligonucleotide primers in a 100-µl final reaction volume for PCR amplification. The sense primer for PCR amplification was a (1:1) mixture of the oligonucleotides 5'-GACAAACGCATGAACAG-3' and 5'-GACAAGCGCATGAACAG-3', corresponding to nucleotides 1678-1694 and 1657-1693 of bovine p85alpha and bovine p85beta cDNAs, respectively. The oligonucleotide sequence 5'-GACAAACGCATGAACAG-3' is identical in bovine and mouse p85alpha (17, 19). The antisense primer was the same one used for reverse transcription. Based on p85alpha and p85beta cDNA sequences, PCR amplification with these primers should generate cDNA products of 386 and 389 bases for p85alpha and p85beta , respectively. 30 cycles of PCR were performed with denaturation at 95 °C for 1 min, annealing at 50 °C for 1 min, and extension at 72 °C for 1 min. PCR products were 35S-labeled by using a sense primer phosphorylated with T4 polynucleotide kinase (Life Technologies, Inc.) in the presence of [35S]ATP. Amplified cDNA fragments were precipitated with ethanol, resolved on a 6% denaturing polyacrylamide gel, and visualized by autoradiography. Scanning optical densitometry (Molecular Dynamics, Sunnyvale, CA) was performed to quantify the relative amounts of amplified cDNA species.

Cell Lysis and Immunoprecipitation of PI 3-Kinase

After incubation in serum-free medium without or with dexamethasone for the indicated times, cells were left untreated or stimulated with IGF-I (100 nM) for 10 min, washed once with ice-cold phosphate-buffered saline containing 100 µM sodium orthovanadate and twice with 20 mM Tris-HCl (pH 7.6) containing 137 mM NaCl, 1 mM MgCl2, 1 mM CaCl2, and 100 µM sodium orthovanadate (Buffer A). The cells were lysed in Buffer A (1 ml/150-mm dish) containing 1% Nonidet P-40, 10% glycerol, 10 mM sodium pyrophosphate, 10 mM sodium fluoride, 2 mM EDTA, 2 mM phenylmethylsulfonyl fluoride, 4 µg/ml leupeptin, and 2 mM sodium orthovanadate (lysis buffer). Insoluble material was removed by centrifugation at 12,000 × g for 10 min at 4 °C, the protein concentration in the resulting supernatant was determined with the Bradford dye binding assay (41), and the final protein concentration was adjusted to 2 mg/ml with lysis buffer.

Immunoprecipitation was carried out by incubation of the cell lysate overnight at 4 °C with anti-IRS-1 antibodies and adsorption of resulting immune complexes to protein A-Sepharose beads for 2 h at 4 °C. The pelleted beads were washed successively in phosphate-buffered saline containing 1% Nonidet P-40 and 100 µM sodium orthovanadate (three times), 100 mM Tris-HCl, pH 7.6, containing 500 mM LiCl and 100 µM sodium orthovanadate (three times), and 10 mM Tris-HCl, pH 7.6, containing 100 mM NaCl, 1 mM EDTA, and 100 µM sodium orthovanadate (twice).

PI 3-Kinase Assay

The washed immunoprecipitates were resuspended in 50 µl of 10 mM Tris-HCl, pH 7.6, containing 100 mM NaCl, 1 mM EDTA, and 100 µM sodium orthovanadate, and then combined with 10 µl of 100 mM MgCl2 and 10 µl of 2 µg/µl phosphatidylinositol (Avanti) that had been sonicated in 10 mM Tris-HCl, pH 7.6, containing 1 mM EGTA. The PI 3-kinase reaction was started by the addition of 10 µl of 10 mM ATP containing 30 µCi of [gamma -32P]ATP. After 10 min at 22 °C with constant vortexing, the reaction was stopped by the addition of 20 µl of 8 N HCl and 160 µl of chloroform/methanol (1:1, v/v). The mixture was vigorously mixed and centrifuged to separate the phases, and the lower organic phase was removed and applied to a silica gel TLC plate precoated with 1% potassium oxalate (Merck, Darmstadt, Germany). The plates were developed in chloroform/methanol/water/ammonia (60:47:11.3:2, v/v), as described previously (36). The PI-3 product was identified by its comigration with a PI-4 standard and quantitated by scanning densitometry.

Immunoblotting

For identification and quantitation of specific proteins, cell lysates were prepared with 1% Nonidet P-40 as described above and analyzed by immunoblotting either directly or following immunoprecipitation with anti-IRS-1, anti-p85, or anti-p110 antibodies, as indicated. Immunoprecipitates or total cell lysates for immunoblotting were boiled in Laemmli buffer with 100 mM dithiothreitol for 4 min, electrophoresed on 8% SDS-polyacrylamide gels, and transferred by electroblotting onto nitrocellulose sheets (Schleicher & Schuell) as described previously (37). The transfer buffer used was 10 mM Tris, 192 mM glycine, 20% methanol (v/v), and 0.02% SDS, and blotting was carried out at 80 volts for 2.5 h. The membranes were incubated with anti-IRS-1, anti-p85, anti-p85alpha , or anti-p110 antibodies as appropriate under conditions reported previously (37). Specific protein bands on autoradiographic images were quantified by scanning optical densitometry, and the data were expressed using arbitrary units normalized to control values within each gel.

Metabolic ([35S]Methionine) Labeling of L6 Cells

Subconfluent cell monolayers in 100-mm dishes were washed twice in phosphate-buffered saline and incubated in serum-free, methionine-free MEM containing 0.1 mCi/ml Tran35S-label at 37 °C for 20 h. Cell lysates then were prepared as described above and precleared by mixing for 16 h at 4 °C with 1 µl of normal goat serum (pre-adsorbed to 30 µl settled volume of protein A-Sepharose) for each ml of lysate. Anti-IRS-1 antibody was added (5 µg adsorbed for 2 h at 4 °C to 30 µl of protein A-Sepharose for each ml of precleared supernatant) and mixed for 4 h at 4 °C. The Sepharose beads were washed as described previously, boiled in Laemmli buffer with 100 mM dithiothreitol for 4 min, and the solubilized proteins electrophoresed on 8% SDS-polyacrylamide gels. Gels were prepared for fluorography using AmplifyTM (Amersham Int., Little Chalfont, United Kingdom), dried at 80 °C under vacuum, and exposed to Kodak XAR-5 film at -80 °C for 6-36 h.

Statistical Analysis

Data are presented as mean ± S.E. Statistical analysis was performed by paired and unpaired Student's t tests as appropriate.


RESULTS

Identification of p85alpha and p85beta Isoforms of PI 3-Kinase in L6 Myoblasts

Two isoforms of the p85 regulatory subunit of PI 3-kinase have been described, p85alpha and p85beta , that are expressed in several, although not all, cell types (16, 19). Previous work has demonstrated that p85 is expressed in rat skeletal muscle, but the isoform pattern in this tissue is not known (42). To investigate the expression of p85 isoforms in rat L6 skeletal muscle cells, we employed polyclonal antibodies to the full-length 85-kDa subunit of p85alpha that detect both p85alpha and p85beta (anti-p85) and a monoclonal antibody raised against a 19-kDa fragment corresponding to the COOH terminus of p85alpha that specifically recognizes p85alpha (anti-p85alpha ). As shown in Fig. 1A, two distinct protein species of 85 and 87 kDa were detected by direct immunoblotting with the isoform-nonspecific anti-p85 antibodies. The apparent molecular weights of these two protein species are similar to the reported size of p85alpha and p85beta expressed in a reticulocyte lysate expression system (19). Immunoprecipitation of Nonidet P-40 extracts of L6 cells with anti-p85 prior to immunoblotting produced similar results, although the ratio of immunoreactive p85alpha to immunoreactive p85beta was considerably greater as compared to direct immunoblotting (Fig. 1A), likely reflecting the relatively higher affinity of anti-p85 antibodies for native as compared to denatured p85alpha . Immunoblotting of these immunoprecipitates with the alpha  isoform-specific antibody anti-p85alpha confirmed the identity of the lower 85-kDa protein as p85alpha (Fig. 1B). These data indicate that both p85alpha and p85beta are expressed in rat L6 myoblasts, migrating as 85- and 87-kDa proteins, respectively, on SDS-polyacrylamide gels.


Fig. 1. Expression of p85alpha and p85beta isoforms of PI 3-kinase in L6 myoblasts. Total cell lysates from L6 myoblasts were obtained as described under "Experimental Procedures" and either left untreated or immunoprecipitated with antibodies to the p85 subunit of PI 3-kinase (anti-p85). Total cell lysates or Sepharose-bound immune complexes were resolved by SDS-PAGE on 8% polyacrylamide gels and analyzed by protein immunoblotting using (A) anti-p85 antibodies (Ab) or (B) a monoclonal antibody specific to p85alpha only (anti-p85alpha ). The p85 proteins were detected with 125I-protein A.
[View Larger Version of this Image (19K GIF file)]


Regulation of p85alpha , p85beta , and p110 Expression

To investigate the effects of the glucocorticoid dexamethasone on the cellular content of p85alpha and p85beta , serum-starved L6 myoblasts were incubated in the presence or absence of 1 µM dexamethasone for different times, and the total cell content of p85alpha and p85beta was determined by immunoblotting with the polyclonal anti-p85 antibody. The content of p85alpha and p85beta did not change in control L6 myoblasts over the 72-h study period (Fig. 2A). In cells treated with 1 µM dexamethasone, the amount of p85alpha progressively increased in a time-dependent manner (Fig. 2A). After 72 h of treatment, p85alpha content was approximately 4-fold higher in dexamethasone-treated L6 myoblasts compared to control (Fig. 2B; p < 0.05). By contrast, dexamethasone did not alter the amount of p85beta (Fig. 2, A and B), indicating that the effect on the alpha  isoform of p85 was specific.


Fig. 2. Effects of dexamethasone on p85alpha and p85beta content in L6 myoblasts. L6 myoblasts were grown in serum-free medium in the presence or absence of 1 µM dexamethasone (Dex) for the indicated times. Total cell lysates were separated by SDS-PAGE on 8% polyacrylamide gels under reducing conditions and analyzed by protein immunoblotting using polyclonal anti-p85 antibody and 125I-protein A. Panel A shows representative autoradiograms and panel B the quantitation of p85alpha and p85beta in multiple experiments (n = 5) performed with incubation in the presence or absence of dexamethasone for 72 h. Open bars, control cells; shaded bars, cells treated with 1 µM dexamethasone for 72 h. *, p < 0.05 versus control cells, paired t test.
[View Larger Version of this Image (32K GIF file)]


To determine whether the increase in the p85alpha regulatory subunit of PI 3-kinase was associated with a coordinate increase in the catalytic p110 subunit, similar L6 myoblast preparations were analyzed by immunoblotting with anti-p110, a specific monoclonal antibody raised against mouse p110 (26). As shown in Fig. 3A, one protein band of 110 kDa was recognized by anti-p110 in myoblast extracts. Dexamethasone treatment for 72 h increased p110 content by 38% (Fig. 3B; p < 0.05). However, the magnitude of this response was much less than the 300% increase in p85alpha (Fig. 2A), indicating that the effects of dexamethasone on the regulatory subunit p85alpha and the catalytic subunit p110, respectively, were not coordinate.


Fig. 3. Dexamethasone regulation of p110 cell content in L6 myoblasts. Cells were grown in serum-free medium in the presence or absence of 1 µM dexamethasone (Dex) for 72 h. Total cell lysates were separated by SDS-PAGE on 8% polyacrylamide gels under reducing conditions and analyzed by protein immunoblotting using anti-p110 antibody and 125I-protein A to detect the catalytic p110 subunit. Panel A shows a representative autoradiogram and panel B the quantitation of p110 in multiple experiments (n = 3). Open bars, control cells; shaded bars, cells treated with 1 µM dexamethasone for 72 h. *, p < 0.05 versus control cells, paired t test.
[View Larger Version of this Image (14K GIF file)]


To assess whether augmentation of p85alpha versus p85beta by dexamethasone could involve a selective increase in p85alpha mRNA, p85alpha and p85beta mRNA levels were measured by quantitative PCR. For this purpose, total RNA was extracted from cells incubated in the presence or absence of 1 µM dexamethasone for 48 h and subjected to reverse transcription and PCR amplification. The p85alpha and p85beta mRNAs were co-amplified in the same PCR reaction using primers complementary to identical or highly homologous nucleotide sequences in the p85alpha and p85beta genes that flank intervening fragments of different length. 35S-dATP was included in the PCR mixture during the reaction and resulting 35S-labeled PCR products were resolved on a denaturing acrylamide gel and visualized by autoradiography. The correct size of the PCR fragments was confirmed by comparison with a sequencing reaction run on the same gel (not shown). A representative autoradiogram of the PCR products is illustrated in Fig. 4A. The products of 386 and 389 bases correspond to the PCR products obtained by amplification of p85alpha and p85beta mRNA, respectively. With this method, the p85beta PCR product was predominant over the p85alpha PCR product, likely reflecting higher p85beta than p85alpha mRNA levels in control L6 myoblasts (ratio of 10:1, with a similar number of 35S-labeled adenylic acid molecules in either PCR fragment). Dexamethasone treatment did not alter p85beta mRNA levels, but induced a 3-fold increase in the amount of p85alpha mRNA compared to control (Fig. 4B). These results are consistent with the observed effects of dexamethasone on p85alpha and p85beta protein levels, indicating that the specific augmentation of p85alpha protein content in L6 myoblasts can be explained by increased levels of p85alpha mRNA.


Fig. 4. Dexamethasone effects on p85alpha and p85beta mRNA content in L6 myoblasts. Cells were grown in serum-free MEM + 0.5% bovine serum albumin in the presence or absence of 1 µM dexamethasone (Dex) for 48 h. Total RNA was extracted and p85alpha and p85beta mRNAs were co-amplified in the same PCR reaction by using primers designed to be complementary to identical or highly homologous nucleotide sequences in the p85alpha and p85beta genes that flank fragments of different lengths. 35S-dATP was included in the PCR mixture, and resulting 35S-labeled PCR products were resolved on a denaturing acrylamide gel and visualized by autoradiography, as shown in A. The correct size of the PCR fragments was confirmed by comparison with a sequencing reaction which was run on the same gel (not shown). The products of 386 and 389 bases correspond to the PCR products obtained by amplification of p85alpha and p85beta mRNA, respectively. B, quantitation of p85alpha and p85beta mRNAs in multiple experiments (n = 3). Open bars, control cells; shaded bars, cells treated with 1 µM dexamethasone for 48 h. *, p < 0.05 versus control cells, paired t test.
[View Larger Version of this Image (24K GIF file)]


PI 3-Kinase Activity Associated with IRS-1

The mechanism of PI 3-kinase activation in L6 cells stimulated with IGF-I involves association of the p85 subunit to tyrosine-phosphorylated residues of the substrate IRS-1 and subsequent activation of the lipid kinase intrinsic to the p110 subunit. Although IGF-I also increases the amount of PI 3-kinase activity recoverable in anti-IGF-I receptor immunoprecipitates, receptor-associated activity represents a minor fraction compared to IRS-1-associated PI 3-kinase activity in L6 myoblasts (36). Since dexamethasone treatment induced a marked increase in the cellular content of p85alpha not paralleled by similar changes in either p85beta or p110, the cellular pool of p85alpha should be in excess relative to other PI 3-kinase components. The consequences of the cellular excess of p85alpha on activation of IRS-1-associated PI 3-kinase were studied by measuring PI 3-kinase activity in IRS-1 immunoprecipitates. Antibody to the carboxyl terminus of rat IRS-1 precipitated 70-80% of immunoreactive IRS-1 from total cell lysates of L6 myoblasts (not shown). In control cells, IGF-I stimulation induced a rapid and marked (42-fold) increase in the amount of PI 3-kinase activity assayed in vitro with [32P]ATP and phosphatidylinositol in reconstituted IRS-1 immunoprecipitates (Fig. 5A). In cells treated with 1 µM dexamethasone for 72 h, there was no difference in the basal level of PI 3-kinase activity associated with IRS-1, but IGF-1 stimulation induced only a 23-fold increase in IRS-1-associated PI 3-kinase activity (Fig. 5A). Thus, in comparison with control cells, dexamethasone reduced by 45% the level of IGF-I-stimulated PI 3-kinase activity associated with IRS-1 (Fig. 5B).


Fig. 5. Dexamethasone effect on IRS-1-associated PI 3-kinase activity. L6 myoblasts were incubated in the presence or absence of 1 µM dexamethasone (Dex) for 72 h, and then stimulated with 100 nM IGF-I. PI 3-kinase activity was measured in anti-IRS-1 immunoprecipitates by in vitro assay with [32P]ATP and phosphatidylinositol, followed by analysis of phosphorylated lipids by thin layer chromatography as described under "Experimental Procedures." The autoradiogram in A shows a representative experiment performed with IGF-I stimulation of intact cells for 10 min. The position of PI 3-phosphate is indicated. The bar graph in B shows the quantitation of multiple experiments (n = 4). Open bars and shaded bars represent control and dexamethasone-treated cells, respectively. *, p < 0.05 versus control cells, paired t test.
[View Larger Version of this Image (32K GIF file)]


Tyrosine Phosphorylation and Cellular Content of IRS-1

The reduced levels of IRS-1-associated PI 3-kinase activity despite the marked increase in p85alpha protein content in dexamethasone-treated L6 myoblasts could be explained by several mechanisms, including decreased tyrosine phosphorylation and/or cellular content of IRS-1 protein, impaired association between p85 proteins and tyrosine-phosphorylated IRS-1, altered "coupling" between p85 and the catalytic subunit p110, or a combination of these factors. To investigate the tyrosine phosphorylation and cellular content of IRS-1, Nonidet P-40 extracts from control and dexamethasone-treated L6 myoblasts were resolved on 7% polyacrylamide gels, transferred to nitrocellulose, and subjected to immunoblotting with anti-PY or anti-IRS-1 antibodies. The effects of dexamethasone on IGF-I stimulation of IRS-1 tyrosine phosphorylation are illustrated in the autoradiograph in Fig. 6A and quantitated in the bar graph in Fig. 6B. Maximum IRS-1 tyrosine phosphorylation was modestly but significantly decreased in dexamethasone-treated compared with control cells (25% decrease, p < 0.05). In addition, the amount of IRS-1 protein was markedly reduced to 35% of control levels (p < 0.05) by dexamethasone (Fig. 6C), as reported previously (36). The decrease in IRS-1 protein levels occurred more rapidly than the increase in p85alpha protein levels, such that IRS-1 protein was reduced to 40% of control after only 12 h of exposure to dexamethasone (not shown). The greater decrease in protein content than tyrosine phosphorylation of IRS-1 resulted in an approximately 2-fold increase in the ratio of tyrosine-phosphorylated IRS-1 to total IRS-1 in L6 myoblasts treated with dexamethasone (Fig. 6C).


Fig. 6. Effects of dexamethasone on IRS-1 tyrosine phosphorylation and protein content. L6 cells were incubated in the presence or absence of 1 µM dexamethasone (Dex) for 72 h and then stimulated with 100 nM IGF-I for 10 min or left untreated. Total cell lysates were resolved on 7% polyacrylamide gels and subjected to immunoblotting with either anti-PY or anti-IRS-1 antibodies, as described under "Experimental Procedures." The autoradiograph in A shows a representative immunoblot of tyrosyl phosphoproteins from control and dexamethasone-treated L6 myoblasts. Quantitation of IRS-1 tyrosine phosphorylation and protein content from multiple experiments is shown in B and C (left panel), respectively. The bar graph in C (right panel) illustrates the ratio of tyrosine phosphorylated to total IRS-1 in control and dexamethasone-treated cells. Open bars and shaded bars represent control and dexamethasone-treated cells, respectively. *, p < 0.05 versus control cells, paired t test.
[View Larger Version of this Image (32K GIF file)]


Association of PI 3-Kinase Subunits with IRS-1

The reduced level of tyrosine-phosphorylated IRS-1 in L6 myoblasts treated with dexamethasone could result in decreased association of this protein with p85, leading to impaired activation of PI 3-kinase. To investigate this possibility, the association of IRS-1 with PI 3-kinase regulatory and catalytic subunits was studied both with metabolic labeling experiments in which anti-IRS-1 immunoprecipitates were isolated from [35S]methionine-labeled cells (Fig. 7), and with immunoblotting analysis of IRS-1 immunoprecipitates using antibodies specific to p85alpha , p85beta , or p110 (Figs. 8 and 9).


Fig. 7. Association of metabolically labeled proteins with immune complexes of IRS-1. L6 myoblasts were metabolically labeled with [35S]methionine in the presence or absence of 1 µM dexamethasone (Dex) for 20 h. Prior to lysis, cells were stimulated with 100 nM IGF-I for 10 min or left untreated. Proteins were then immunoprecipitated from cleared lysates using anti-IRS-1 antibody, as described under "Experimental Procedures." Immune complexes were resolved by 8% SDS-PAGE and subjected to fluorography. A representative of three experiments is shown.
[View Larger Version of this Image (67K GIF file)]



Fig. 8. Effects of dexamethasone on IRS-1/p85alpha complex formation. Total lysates from L6 myoblasts were subjected to immunoprecipitation with either anti-IRS-1 (panels A and B) or anti-p85 antibodies (panel C). Immunoprecipitates (IP) were resolved on 8% polyacrylamide gels and subjected to immunoblotting with the indicated antibodies, as described under "Experimental Procedures." In each blot, lane numbers represent the following conditions: 1, control cells in the unstimulated state; 2, cells treated with 1 µM dexamethasone for 72 h in the unstimulated state; 3, control cells stimulated with 100 nM IGF-I for 10 min; 4, cells treated with 1 µM dexamethasone for 72 h and subsequently stimulated with 100 nM IGF-I for 10 min.
[View Larger Version of this Image (43K GIF file)]



Fig. 9. Effects of dexamethasone on IRS-1/p110 complex formation. Total lysates were prepared from control or dexamethasone (Dex)-treated L6 myoblasts and subjected to immunoprecipitation with anti-IRS-1 antibody. Immunoprecipitates were then resolved on 8% polyacrylamide gels and subjected to immunoblotting with anti-p110 antibody, as described under "Experimental Procedures." Panel A shows a representative experiment, and the bar graph in panel B shows the quantitation of p110 in IRS-1 immunoprecipitates from multiple experiments (n = 3). Open bars represent control cells and shaded bars represent cells treated with 1 µM dexamethasone for 72 h. *, p < 0.05 versus control cells, paired t test. In panel C, lysates from control and dexamethasone-treated L6 myoblasts were subjected to immunoprecipitation with anti-p110 antibody followed by immunoblotting with anti-IRS-1 antibody.
[View Larger Version of this Image (24K GIF file)]


For metabolic labeling studies, L6 myoblasts were labeled with [35S]methionine in the absence or presence of 1 µM dexamethasone for 20 h. Under these experimental conditions, steady-state levels of protein labeling were achieved (not shown). IRS-1 immunoprecipitates were then obtained as described under "Experimental Procedures" and subjected to SDS-PAGE followed by fluorography. As compared with the basal state, IGF-I stimulation induced the association of three protein species of 85, 87, and 110 kDa, respectively, with IRS-1 in control cells (Fig. 7, first and second lanes). These protein species were found to be the only detectable 35S-labeled proteins in the molecular mass range from 40 to 230 kDa undergoing increased association with IRS-1 upon IGF-I stimulation. Based on their electrophoretic mobilities, the 85-, 87-, and 110-kDa proteins are likely to represent the p85alpha , p85beta , and p110 subunits of PI 3-kinase. In consideration of the similar number of methionine and cysteine residues contained in p85 isoforms (9 methionines and 6 cysteines in p85alpha , 8 methionines and 6 cysteines in p85beta ) (19), the stoichiometry of p85alpha and p85beta in the IRS-1 complex upon IGF-I stimulation appears to be 1:1.7 (Fig. 7, second lane), indicating that more p85beta than p85alpha associates with IRS-1 after stimulation with IGF-I in L6 myoblasts. The 110-kDa band induced by IGF-I appears as a single protein species and shows higher labeling compared to the p85 proteins (Fig. 7, second lane), likely reflecting the greater number of methionine and cysteine residues in p110 compared to p85 (a total of 72 in bovine p110) (20) and the potential association of multiple p110 molecules with IRS-1 through distinct p85 proteins (19). IGF-I stimulation also induced the association of 35S-labeled p85alpha , p85beta , and p110 with IRS-1 in dexamethasone-treated L6 myoblasts (Fig. 7, third and fourth lanes). However, the amounts of IRS-1 associated 35S-labeled p85alpha and 35S-labeled p85beta in IRS-1 immunoprecipitates were approximately 200 and 70%, respectively, in L6 myoblasts treated with dexamethasone compared to control cells, such that the p85alpha /p85beta ratio was increased. In spite of the increase in IRS-1 associated p85alpha , the amount of 35S-labeled p110 was found to be decreased by 30% in cells treated with dexamethasone (Fig. 7, fourth lane). Thus, the increase in IRS-1 associated p85alpha was not associated with a coordinate increase in IRS-1 associated p110.

The levels of IRS-1 associated p85alpha and p85beta in control and dexamethasone-treated L6 myoblasts also were determined by immunoblotting with anti-p85 antibody (Fig. 8A, left panel). To specifically detect p85alpha , similar immunoprecipitates were also analyzed with a monoclonal antibody to p85alpha (Fig. 8A, right panel). Quantitation of the two p85 isoforms in IRS-1 immunoprecipitates is presented in Table I. Small amounts of both p85alpha and p85beta were associated with IRS-1 in the basal state, and the amount of immunoreactive p85beta was approximately 2-fold greater than the amount of p85alpha (alpha /beta ratio = 0.5). IGF-I stimulation increased the amount of p85alpha and p85beta associated with IRS-1 by 9.4- and 5.5-fold, respectively, resulting in a slight increase in the alpha /beta ratio to 0.85. Although this experiment does not provide direct quantitation of the absolute amounts of p85alpha and p85beta , it should be noted that the alpha /beta ratio detected by direct immunoblotting with anti-p85 antibody was considerably greater than the alpha /beta ratio in IRS-1 immunoprecipitates (compare Figs. 1A and 8A). This indicates that a greater proportion of cellular p85beta was engaged in complexes with IRS-1 than the comparable fraction of cellular p85alpha . As shown in Fig. 8A and Table I, in dexamethasone-treated L6 myoblasts, a considerably greater amount of p85alpha and a moderately lower amount of p85beta were associated with IRS-1 in the absence of IGF-I stimulation (430 and 78% of control levels, respectively, p < 0.05), such that the alpha /beta ratio was increased to 2.69. IGF-I stimulation increased the amounts of both p85alpha and p85beta in IRS-1 immunoprecipitates of dexamethasone-treated cells (4.4- and 4.1-fold, respectively). However, in comparison with IGF-I stimulated cells not treated with dexamethasone, IRS-1-associated p85alpha was increased and p85beta was decreased (205 and 60% of control levels, respectively, p < 0.05). Thus, the alpha /beta ratio in IGF-I stimulated cells was further increased to 2.88 (Table I). These results indicate that IRS-1 is complexed to greater amounts of p85alpha and reduced amounts of p85beta both in the basal state and after stimulation with IGF-I in dexamethasone-treated compared with control L6 myoblasts. It should be noted that complex formation between IRS-1 and p85alpha was increased in dexamethasone-treated L6 myoblasts, even though the levels of total and tyrosine-phosphorylated IRS-1 in the immunoprecipitates analyzed in these experiments were decreased by 68 ± 15% and 27 ± 12%, respectively (Fig. 8B, p < 0.5), in agreement with the results presented in Fig. 6. These findings were confirmed by immunoprecipitation with antibodies to p85alpha and subsequent immunoblotting with anti-IRS-1 or anti-PY antibodies, as illustrated in Fig. 8C. Taken together, these results indicate that considerably greater amounts of p85alpha and moderately lower amounts of p85beta , respectively, were associated with IRS-1 in L6 myoblasts treated with dexamethasone, in agreement with the results from metabolic labeling studies (Fig. 7). Thus, the increase in total p85alpha observed in L6 myoblasts treated with dexamethasone correlates with an increase in IRS-1-associated p85alpha . This indicates that the inhibition of PI 3-kinase activation cannot be attributed to reduced complex formation between IRS-1 and p85 proteins.

Table I.

Quantitation of p85alpha and p85beta subunits of PI 3-kinase in IRS-1 immunoprecipitates

Experiments were carried out using antibodies that react with both p85alpha and p85beta isoforms of p85. Data are expressed as arbitrary units with immunoreactive p85beta normalized to a value of 1. Dexamethasone L6 myoblasts treated with 1 µM dexamethasone for 72 h.
Basal control IGF-I control Fold increase control Basal dexamethasone IGF-I dexamethasone Fold increase dexamethasone

 alpha 0.50 4.70a 9.4 2.15a 9.50b;c 4.4d
 beta 1.00 5.50a 5.5 0.78a 3.30b;c 4.1
 alpha /beta e 0.50 0.85a 2.69a 2.88a;e

a p < 0.05 versus basal control.
b p < 0.05 versus basal dexamethasone.
c p < 0.05 versus IGF-I control.
d p < 0.05 versus fold increase control.
e alpha /beta , ratio of p85alpha versus p85beta in IRS-1 immune complexes.

Decreased IRS-1-associated PI 3-kinase activity (Fig. 5) in spite of the marked increase in IRS-1-associated p85alpha in L6 myoblasts treated with dexamethasone raises the possibility that a significant amount of the p85alpha in IRS-1 immunoprecipitates may not exist as a complex with the p110 catalytic subunit of PI 3-kinase. To directly measure the amount of the p110 subunit associated with IRS-1, proteins from control or dexamethasone-treated L6 myoblasts were subjected to immunoprecipitation with IRS-1 antibody followed by immunoblotting with monoclonal antibody specific for p110 (26) (Fig. 9A). In the absence of IGF-I stimulation little p110 was detectable in IRS-1 immunoprecipitates from control or dexamethasone-treated cells. Stimulation of control cells with 100 nM IGF-I for 10 min increased the amount of p110 associated with IRS-1 by 3.9-fold (Fig. 9, A and B). In dexamethasone-treated L6 myoblasts, although the amount of p110 in IRS-1 immunoprecipitates also increased upon IGF-I stimulation, the amount of p110 associated with IRS-1 was decreased by 41% in comparison with control cells (Fig. 9, A and B, p < 0.05). These results are similar to the results presented in Fig. 7, showing reduced levels of 35S-labeled p110 associated with IRS-1 upon IGF-I stimulation in dexamethasone-treated L6 myoblasts. If related to the level of tyrosine-phosphorylated IRS-1 in IRS-1 immunoprecipitates (Fig. 8B), IRS-1 associated p110 was still decreased by 22% in dexamethasone-treated cells compared to control. This correlates with the finding of a 25% decrease in the level of IRS-1 associated PI 3-kinase activity corrected for the level of tyrosine-phosphorylated IRS-1 in response to dexamethasone treatment. These results support the concept that PI 3-kinase inhibition by dexamethasone cannot be entirely explained by decreased tyrosine phosphorylation of IRS-1. The reduced complex formation between IRS-1 and p110 in dexamethasone-treated cells was confirmed by carrying out the reverse experiment with p110 immunoprecipitation followed by anti-IRS-1 immunoblotting (Fig. 9C). These observations indicate that IRS-1 is complexed with p85alpha molecules that are not coupled stoichiometrically with p110 in L6 myoblasts treated with dexamethasone. The decreased amounts of the p110 catalytic subunit in IRS-1 immunoprecipitates from L6 myoblasts treated with dexamethasone correlate with and can account for the observed decrease in the levels of PI 3-kinase activity.


DISCUSSION

This study demonstrates that both the cellular amounts of the various subunits constituting the PI 3-kinase enzyme complex and PI 3-kinase subunit association with tyrosine-phosphorylated IRS-1 are differentially regulated by the glucocorticoid dexamethasone in undifferentiated L6 skeletal muscle cells. Dexamethasone markedly increased p85alpha in L6 myoblasts, but did not alter the levels of p85beta and induced only a modest increase in cellular p110 content. Under these conditions, a greater amount of p85alpha and reduced amounts of both p85beta and p110 were recruited to the IGF-I receptor substrate IRS-1 upon hormone stimulation. In addition, the activity of PI 3-kinase measured in IRS-1 immune complexes was significantly decreased by dexamethasone, likely reflecting the reduced amounts of IRS-1-associated p110 catalytic subunit.

Glucocorticoids have been reported to increase the amount of p85 protein in rat skeletal muscle (42) and in F442A adipocytes (43). In these previous studies, the p85 isoform pattern was not determined and, therefore, it is not known whether the effects of dexamethasone were isoform-specific. In L6 myoblasts, the increase in p85alpha protein content was associated with an increase in p85alpha mRNA and no change in p85beta mRNA, suggesting that dexamethasone may act by specifically increasing expression of the p85alpha gene. The p85alpha and p85beta isoforms possess 62% overall identity at the amino acid level and 58% nucleotide identity and, thus, are thought to be encoded by two distinct but related genes (19). Information on p85 gene structure is very limited at present and, in future studies, it will be important to identify the gene regulatory elements that dictate the tissue distribution of the two p85 isoforms as well as the glucocorticoid responsiveness limited to p85alpha . Our data would indicate that glucocorticoid response elements may be identified exclusively in the p85alpha gene (and not in the p85beta gene).

The selective regulation of the alpha  isoform of p85 by dexamethasone supports the concept that p85alpha and p85beta may have distinct biological roles. Although the related p85alpha and p85beta regulatory subunits both have been shown to form stable complexes with the catalytic p110 component of PI 3-kinase (21, 22), functional differences of p85alpha as compared to p85beta previously have been reported. Studies conducted in T-lymphocytes have demonstrated that the two p85 isoforms have a different phosphorylation pattern upon T-cell activation (44). Following activation of the CD3 antigen complex in T-cells, rapid serine phosphorylation of p85alpha was observed, whereas phosphorylation of p85beta was unchanged. In addition, the catalytic subunit p110 was shown to undergo rapid threonine phosphorylation when associated with p85beta but not with p85alpha . It has recently been reported that much larger stimulation of PI 3-kinase is found in p85alpha compared to p85beta immunoprecipitates upon insulin stimulation of CHO-T cells, even though both p85alpha and p85beta associate with IRS-1(45). This has led to the suggestion that insulin causes recruitment of both p85alpha and p85beta regulatory subunits to IRS-1 signaling complexes, but the activity of IRS-1-associated PI 3-kinase is stimulated only in the p85alpha ·p110 complex, with little or no stimulation of the p85beta ·p110·PI 3-kinase complex. The results in the current study demonstrating specific augmentation of p85alpha protein content by dexamethasone indicate for the first time that the control of p85alpha and p85beta expression represents an additional level of differential regulation of the two p85 isoforms.

IGF-I stimulation of L6 myoblasts induced a severalfold increase in the association of both p85alpha and p85beta isoforms with IRS-1 immune complexes. Both p85 isoforms have reportedly been shown to associate with IRS-1 signaling complexes upon insulin stimulation in COS-1 cells transiently transfected with the insulin receptor and in CHO-T cells stably overexpressing the insulin receptor (45). In the latter study, the alpha /beta ratio in IRS-1 immune complexes generally reflected the alpha /beta ratio in the total cell lysate, indicating no preferential recruitment of a given p85 isoform to IRS-1 (45). By contrast, our results indicate that p85beta may preferentially associate with IRS-1 in signaling complexes, since the association of p85beta with IRS-1 immune complexes was greater quantitatively than that of p85alpha in response to IGF-I stimulation (Figs. 7 and 8). It is possible that association of p85alpha and p85beta with IRS-1 signaling complexes may be modulated in a cell context specific manner and differ in cell lines expressing high levels of insulin receptors in which hyperphosphorylation of IRS-1 may occur. Interestingly, the amount of p85alpha in anti-phosphotyrosine immunoprecipitates from PDGF-stimulated L6 myoblasts was significantly higher than the amount of p85beta and thus the alpha /beta ratio was much greater than in IRS-1 immune complexes.2 This suggests that association of p85alpha and p85beta with tyrosine-phosphorylated proteins in L6 skeletal muscle cells may differ depending on the specific protein target (i.e. IRS-1 versus the PDGF receptor).

Ample experimental evidence has established the concept of IRS-1 acting as a "docking protein" capable of simultaneously binding multiple protein components through specific amino acid motifs containing phosphorylated tyrosine residues. GST fusions of the NH2-terminal SH2 domain of p85alpha were found to bind strongly to Tyr608-Met-Pro-Met and Tyr939-Met-Asn-Met and, to a lesser extent, to Tyr461-Ile-Cys-Met and Tyr987-Met-Tyr-Met in IRS-1 (35). At present, it is not known whether the same sites serve also for the two SH2 domains present in p85beta . Although both p85alpha and p85beta were shown to bind simultaneously to a single IRS-1 molecule in COS-1 cells transiently transfected with the insulin receptor, this was not the case in CHO-T cells stably expressing the insulin receptor (45). In the PDGF receptor, Tyr751 is a common binding site for both Nck and p85alpha , indicating that SH2 domains of different signaling molecules can compete for binding to the same phosphorylated tyrosine motif (46). In L6 myoblasts treated with dexamethasone, the increase in IRS-1-bound p85alpha was associated with a coordinate decrease in IRS-1-associated p85beta , which could potentially be explained by p85alpha and p85beta competing for the same binding site(s) on tyrosine-phosphorylated IRS-1.

Dexamethasone induced a cellular excess of p85alpha and a greater number of IRS-1·p85alpha complexes in L6 myoblasts. That the pool of IRS-1-associated p85alpha was largely composed of regulatory subunit lacking the p110 catalytic subunit is indicated by the detection of reduced amounts of IRS-1-associated p110 (demonstrated by both p110 immunoblotting and metabolic labeling experiments) and a corresponding decrease in PI 3-kinase activity. Although there was an increase in p110 protein in total cell lysates following treatment of L6 myoblasts with dexamethasone, this was much less pronounced than the increase in p85alpha protein (38 versus 300%, respectively). In interpreting these results, it is important to note that two p110 proteins (p110alpha and p110beta ) have been identified (20, 24). We have used a monoclonal antibody raised against bovine p110 that recognizes only the p110alpha isoform. Therefore, it is not known whether or not dexamethasone affects cellular levels of p110beta and what fraction of IRS-1-associated p85alpha in dexamethasone-treated cells was coupled with p110beta . However, the decrease in IRS-1-associated p110alpha and IRS-1-associated PI 3-kinase activity in response to dexamethasone were coordinate. In addition, a single 35S-labeled protein of 110 kDa, possibly representing both p110alpha and p110beta , was detectable in IRS-1 immunoprecipitates upon IGF-I stimulation. This band was less intense in L6 myoblasts treated with dexamethasone, confirming that the total amount of IRS-1-associated catalytic p110 subunit was decreased.

A p85 subunit lacking a p110 subunit may have the capacity to bind to the specific tyrosine-phosphorylated motif in target proteins without localizing catalytic activity in the protein-protein signaling complex. Generation of non-coupled (i.e. monomeric or free) p85alpha can be achieved experimentally by transfection and overexpression of the p85alpha cDNA in mammalian cells. When this experiment was performed in 293 cells overexpressing the PDGF receptor, overexpression of p85alpha was shown to completely abrogate activation of PDGF receptor-associated PI 3-kinase activity (28). In addition, microinjection of the p85alpha NH2-terminal SH2 domain into rat 1 fibroblasts overexpressing the insulin receptor was shown to inhibit insulin- and IGF-I-induced DNA synthesis by competing with endogenous PI 3-kinase for binding to IRS-1 (29). These studies support the concept that cellular overexpression of the p85alpha regulatory subunit of the PI 3-kinase complex can lead to inhibition of PI 3-kinase activity and impairment of cell signaling through activation of this enzyme. Accordingly, the excess of free p85alpha induced by dexamethasone in L6 myoblasts may compete with both p85alpha ·p110 and p85beta ·p110 complexes for binding to IRS-1. If there are functional specificities for IRS-1-bound p85alpha and p85beta , respectively, this may have distinct effects by disrupting specific signaling responses not only through IRS-1·p85alpha ·p110 complexes, but also through IRS-1·p85beta ·p110 complexes.

There is evidence that free p85alpha binds to tyrosine-phosphorylated proteins with greater avidity than the intact p85·p110 complex (19, 29). Thus, preferential complex formation between IRS-1 and p85alpha may have occurred in L6 myoblasts treated with dexamethasone. It recently has been suggested that in situ concentrations of PI 3,4,5-P3 synthesized locally by the catalytic subunit of PI 3-kinase may bind to the SH2 domain of p85 and dissociate PI 3-kinase from the tyrosine phosphoprotein (47). The lack of PI 3,4,5-P3 production by the catalytically inactive p85alpha monomer induced by dexamethasone could provide a mechanism conferring greater affinity to this protein for binding to tyrosine-phosphorylated IRS-1 compared to p85alpha ·p110 and p85beta ·p110 complexes. Such a mechanism could also lead to displacement of IRS-1-bound p85beta ·p110 by free p85alpha .

Activation of PI 3-kinase by receptor and nonreceptor protein tyrosine kinases has been implicated in a broad spectrum of cellular responses, including mitogenesis (1, 7, 8), chemotaxis (48, 49), membrane ruffling (5), activation of p70 S6 kinase (50), insulin-dependent GLUT-4 translocation (51), glycogen synthesis (13, 14), activation of integrins in platelets (52), histamine release (53), receptor down-regulation (6), and inhibition of apoptosis (54). All of these biological responses require a functionally active PI 3-kinase enzyme complex that reflects the coordinate expression of both p85 and p110 PI 3-kinase subunits in the cell. The generation of excess p85alpha regulatory subunit relative to the other components of the PI 3-kinase complex along with inhibition of IRS-1-associated PI 3-kinase activity in response to dexamethasone demonstrated in this study suggests a novel mechanism of PI 3-kinase regulation. This mechanism may not be limited to muscle cells and may occur in other cell types under physiological circumstances and/or in disease states characterized by high levels of endogenous cortisol or exogenously administered glucocorticoids.


FOOTNOTES

*   This work was supported in part by the Juvenile Diabetes Foundation and National Institutes of Health Grants DK43038, DK48503, DK50411, Trauma Center Grant GM36428, and Diabetes and Endocrinology Research Center Grant DK36836 (to R. J. S.) and a grant from the Societa' Italiana di Diabetologia (Fondo per la Ricerca Eli Lilly, 1994-1996) (to F. G.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
   Supported by postdoctoral fellowships from the Juvenile Diabetes Foundation International and the Mary K. Iacocca Foundation.
par    Supported by a postdoctoral fellowship from the Max Kade Foundation.
**   To whom reprint requests should be addressed: Research Division, Joslin Diabetes Center, One Joslin Place, Boston, MA 02215. Tel.: 617-732-2474; Fax: 617-732-2650; E-mail: smithr{at}joslab.harvard.edu.
1   The abbreviations used are: PI, phosphatidylinositol; IGF-I, insulin-like growth factor-I; PDGF, platelet-derived growth factor; IRS-1, insulin receptor substrate-1; SH, src homology; p85, regulatory subunit of PI 3-kinase of 85 kDa; p110, catalytic subunit of PI 3-kinase of 110 kDa; MEM, minimal essential medium; PY, phosphotyrosine.
2   F. Giorgino and R. J. Smith, unpublished results.

Acknowledgment

We acknowledge Karen TenDyke for excellent technical support.


REFERENCES

  1. Cantley, L. C., Auger, K. R., Carpenter, C. L., Duckworth, B. C., Graziani, A., Kapeller, R., and Soltoff, S. (1991) Cell 64, 281-302 [Medline] [Order article via Infotrieve]
  2. Serunian, L. A., Haber, M. T., Fukui, T., Kim, J. W., Rhee, S. G., Lowenstein, J. M., and Cantley, L. C. (1989) J. Biol. Chem. 264, 17809-17815 [Abstract/Free Full Text]
  3. Lips, D. L., Majerus, P. W., Gorga, F. R., Young, A. T., and Benjamin, T. L. (1989) J. Biol. Chem. 264, 8759-8763 [Abstract/Free Full Text]
  4. Toker, A., Meyer, M., Reddy, K. K., Falck, J. R., Aneja, R., Aneja, S., Parra, A., Burns, D. J., Ballas, L. M., and Cantley, L. C. (1994) J. Biol. Chem. 269, 32358-32367 [Abstract/Free Full Text]
  5. Kotani, K., Yonezawa, K., Hara, K., Ueda, H., Kitamura, Y., Sakaue, H., Ando, A., Chavanieu, A., Calas, B., and Grigorescu, F. (1994) EMBO J. 13, 2313-2321 [Abstract]
  6. Joly, M., Kazlauskas, A., Fay, F. S., and Corvera, S. (1994) Science 263, 684-687 [Medline] [Order article via Infotrieve]
  7. Fantl, W. J., Escobedo, J. A., Martin, G. A., Turck, C. W., del Rosario, M., McCormick, F., and Williams, L. T. (1992) Cell 69, 413-423 [Medline] [Order article via Infotrieve]
  8. Valius, M., and Kazlauskas, A. (1993) Cell 73, 321-334 [Medline] [Order article via Infotrieve]
  9. Tomiyama, K., Nakata, H., Sasa, H., Arimura, S., Nishio, E., and Watanabe, Y. (1995) Biochem. Biophys. Res. Commun. 212, 263-269 [CrossRef][Medline] [Order article via Infotrieve]
  10. Gould, G. W., Jess, T. J., Andrews, G. C., Herbst, J. J., Plevin, R. J., and Gibbs, E. M. (1994) J. Biol. Chem. 269, 26622-26625 [Abstract/Free Full Text]
  11. Okada, T., Kawano, Y., Sakakibara, T., Hazeki, O., and Ui, M. (1994) J. Biol. Chem. 269, 3568-3573 [Abstract/Free Full Text]
  12. Yeh, J.-I., Gulve, E. A., Rameh, L., and Birnbaum, M. J. (1995) J. Biol. Chem. 270, 2107-2111 [Abstract/Free Full Text]
  13. Shepherd, P. R., Nave, B. T., and Siddle, K. (1995) Biochem. J. 305, 25-28 [Medline] [Order article via Infotrieve]
  14. Yamamoto-Honda, R., Tobe, K., Kaburagi, Y., Ueki, K., Asai, S., Yachi, M., Shirouzu, M., Yodoi, J., Akanuma, Y., Yokoyama, S., Yazaki, Y., and Kadowaki, T. (1995) J. Biol. Chem. 270, 2729-2734 [Abstract/Free Full Text]
  15. Carpenter, C. L., Duckworth, B. C., Auger, K. R., Cohen, B., Schaffhausen, B. S., and Cantley, L. C. (1990) J. Biol. Chem. 265, 19704-19711 [Abstract/Free Full Text]
  16. Fry, M. J, Panayotou, G., Dhand, R., Ruiz-Larrea, F., Gout, I., Nguyen, O., Courtneidge, S. A., and Waterfield, M. D. (1992) Biochem. J. 288, 383-393 [Medline] [Order article via Infotrieve]
  17. Escobedo, J. A., Navankasattusas, S., Kavanaugh, W. M., Milfay, D., Fried, V. A., and Williams, L. T. (1991) Cell 65, 75-82 [Medline] [Order article via Infotrieve]
  18. Skolnik, E. Y., Margolis, B., Mohammadi, M., Lowenstein, E., Fischer, R., Drepps, A., Ullrich, A., and Schlessinger, J. (1991) Cell 65, 83-90 [Medline] [Order article via Infotrieve]
  19. Otsu, M., Hiles, I., Gout, I., Fry, M. J., Ruis-Larrea, F., Panayotou, G., Thompson, A., Dhand, R., Hsuan, J., Totty, N., Smith, A. D., Morgan, S. J., Courtneidge, S. A., Parker, P. J., and Waterfield, M. D. (1991) Cell 65, 91-104 [Medline] [Order article via Infotrieve]
  20. Hiles, I. D., Otsu, M., Volinia, S., Fry, M. J., Gout, I., Dhand, R., Panayotou, G., Ruiz-Larrea, F., Thompson, A., Totty, N. F., Hsuan, J. J., Courtneidge, S. A., Parker, P. J., and Waterfield, M. D. (1992) Cell 70, 419-429 [Medline] [Order article via Infotrieve]
  21. Gout, I., Dhand, R., Panayotou, G., Fry, M. J., Hiles, I., Otsu, M., and Waterfield, M. D. (1992) Biochem. J. 288, 395-405 [Medline] [Order article via Infotrieve]
  22. Pawson, T., and Gish, G. D. (1992) Cell 71, 359-362 [Medline] [Order article via Infotrieve]
  23. Dhand, R., Hara, K., Hiles, I., Bax, B., Gout, I., Panayotou, G., Fry, M. J., Yonezawa, K., Kasuga, M., and Waterfield, M. D. (1994) EMBO J. 13, 511-521 [Abstract]
  24. Hu, P., Mondino, A., Skolnik, E. Y., and Schlessinger, J. (1993) Mol. Cell. Biol. 13, 7677-7688 [Abstract]
  25. Holt, K. H., Olson, A. L., Moye-Rowley, W. S., and Pessin, J. E. (1994) Mol. Cell. Biol. 14, 42-49 [Abstract]
  26. Klippel, A., Escobedo, J. A., Hirano, M., and Williams, L. T. (1994) Mol. Cell. Biol. 14, 2675-2685 [Abstract]
  27. Hu, P., and Schlessinger, J. (1994) Mol. Cell. Biol. 14, 2577-2583 [Abstract]
  28. Hu, P., Margolis, B., Skolnik, E. Y., Lammers, R., Ullrich, A., and Schlessinger, J. (1992) Mol. Cell. Biol. 12, 981-990 [Abstract]
  29. Jhun, B. H., Rose, D. W., Seely, B. L., Rameh, L., Cantley, L. C., Saltiel, A. R., and Olefsky, J. M. (1994) Mol. Cell. Biol. 14, 7466-7475 [Abstract]
  30. Yamamoto, K., Lapetina, E. G., and Moxham, C. P. (1992) Endocrinology 130, 1490-1498 [Abstract]
  31. Backer, J. M., Myers Jr, M. G., Sun, X.-J., Chin, D. J., Shoelson, S. E., Miralpeix, M., and White, M. F. (1993) J. Biol. Chem. 268, 8204-8212 [Abstract/Free Full Text]
  32. Sun, X. J., Wang, L-M., Zhang, Y., Yenush, L., Myers, M. G., Jr., Glasheen, E., Lane, W. S., Pierce, J. H., and White, M. F. (1995) Nature 377, 173-177 [CrossRef][Medline] [Order article via Infotrieve]
  33. Myers, M. G., Jr., Backer, J. M., Sun, X.-J., Shoelson, S. E., Hu, P., Schlessinger, J., Yoakim, M., Schaffhausen, B., and White, M. F. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 10350-10354 [Abstract]
  34. Backer, J. M., Myers, M. G., Jr., Shoelson, S. E., Chin, D. J., Sun, X.-J., Miralpeix, M., Hu, P., Margolis, B., Skolnik, E. Y., Schlessinger, J., and White, M. F. (1992) EMBO J. 11, 3469-3479 [Abstract]
  35. Sun, X.-J., Crimmins, D. L., Myers, M. G., Jr., Miralpeix, M., and White, M. F. (1993) Mol. Cell. Biol. 13, 7418-7428 [Abstract]
  36. Giorgino, F., and Smith, R. J. (1995) J. Clin. Invest. 96, 1473-1483 [Medline] [Order article via Infotrieve]
  37. Giorgino, F., Almahfouz, A., Goodyear, L. J., and Smith, R. J. (1993) J. Clin. Invest. 91, 2020-2030 [Medline] [Order article via Infotrieve]
  38. Sun, X. J., Rothenberg, P., Kahn, C. R., Backer, J. M., Araki, E., Wilden, P. A., Cahill, D. A., Goldstein, B. J., and White, M. F. (1991) Nature 352, 73-77 [CrossRef][Medline] [Order article via Infotrieve]
  39. Chomczynski, P., and Sacchi, N. (1987) Anal. Biochem. 162, 156-159 [CrossRef][Medline] [Order article via Infotrieve]
  40. Pedrini, M. T., Giorgino, F., and Smith, R. J. (1994) Biochem. Biophys. Res. Commun. 202, 1038-1046 [CrossRef][Medline] [Order article via Infotrieve]
  41. Bradford, M. M. (1976) Anal. Biochem. 72, 248-257 [CrossRef][Medline] [Order article via Infotrieve]
  42. Saad, M. J. A., Folli, F., Kahn, J. A., and Kahn, C. R. (1993) J. Clin. Invest. 92, 2065-2072 [Medline] [Order article via Infotrieve]
  43. Saad, M. J. A., Folli, F., Araki, E., Hashimoto, N., Csermely, P., and Kahn, C. R. (1994) Mol. Endocrinol. 8, 545-557 [Abstract]
  44. Baltensperger, K., Kozma, L. M., Jaspers, S. R., and Czech, M. P. (1994) J. Biol. Chem. 269, 28937-28946 [Abstract/Free Full Text]
  45. Reif, K., Gout, I., Waterfield, M. D., and Cantrell, D. A. (1993) J. Biol. Chem. 268, 10780-10788 [Abstract/Free Full Text]
  46. Nishimura, R., Li, W., Kashishian, A., Mondino, A., Zhou, M., Cooper, J., and Schlessinger, J. (1993) Mol. Cell. Biol. 13, 6889-6896 [Abstract]
  47. Rameh, L. E., Chen, C-S., and Cantley, L. C. (1995) Cell 83, 821-830 [Medline] [Order article via Infotrieve]
  48. Wennstrom, S., Siegbahn, A., Koutaro, Y., Arvidsson, A.-K., Heldin, C.-H., Mori, S., and Claesson-Welsh, L. (1994) Oncogene 9, 651-660 [Medline] [Order article via Infotrieve]
  49. Kundra, V., Escobedo, J. A., Kazlauskas, A., Kim, H. K., Rhee, S. G., Williams, L. T., and Zetter, B. R. (1994) Nature 367, 474-476 [CrossRef][Medline] [Order article via Infotrieve]
  50. Chung, J., Grammer, T. C., Lemon, K. P., Kazlauskas, A., and Blenis, J. (1994) Nature 370, 71-75 [CrossRef][Medline] [Order article via Infotrieve]
  51. Cheatham, B., Vlahos, C. J., Cheatham, L., Wang, L., Blenis, J., and Kahn, C. R. (1994) Mol. Cell. Biol. 14, 4902-4911 [Abstract]
  52. Kovacsovics, T. J., Bachelot, C., Toker, A., Vlahos, C. J., Duckworth, B., Cantley, L. C., and Hartwig, J. H. (1995) J. Biol. Chem. 270, 11358-11366 [Abstract/Free Full Text]
  53. Yano, H., Nakanishi, S., Kimura, K., Hanai, N., Saitoh, Y., Fukui, Y., Nonomura, Y., and Matsuda, Y. (1993) J. Biol. Chem. 268, 25846-25856 [Abstract/Free Full Text]
  54. Yao, R., and Cooper, G. M. (1995) Science 267, 2003-2006 [Medline] [Order article via Infotrieve]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.